salmeterol + fluticasone + fenoterol

This combination therapy consists of salmeterol (a long-acting beta-2 agonist), fluticasone propionate (an inhaled corticosteroid), and fenoterol (a short-acting beta-2 agonist). It was specifically evaluated in a clinical trial (NCT01044108) led by Shin-hwar Wu to determine if an individualized dosing schedule based on airway resistance is more effective than a fixed dosing schedule in endotracheally intubated patients with chronic obstructive pulmonary disease (COPD). The regimen utilizes the synergistic effects of rapid-acting and long-acting bronchodilation (via beta-2 adrenergic receptor agonism) and localized anti-inflammatory action (via glucocorticoid receptor activation) to manage acute respiratory failure in COPD patients.

Brand names

SeretideBerotec

Other names

salmeterol/fluticasone plus fenoterol